B

Bristol Myers Squibb

Global biopharma researching, developing, delivering medicines

Regional Echo Liaison

Full-TimeUpdated on 10/1/2026Deadline 10/24/26
$110.9k - $134.4k/yr+ Discretionary incentive cash + Stock opportunities
Senior
Bachelor's
Remote in USA
RemoteHome-based role with 50–70% travel, including overnight and occasional weekend travel.
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • Graduate of an accredited ultrasound program with echocardiography required.
  • An active cardiac ultrasound registry credential, Registered Diagnostic Cardiac Sonographer or Registered Cardiac Sonographer, is required.
  • A minimum of 5 years of adult echocardiography experience.
  • Strong knowledge of hypertrophic cardiomyopathy and familiarity with relevant scientific literature.
  • Ability to interpret and communicate complex clinical data clearly and effectively.
  • Ability to work independently and collaboratively.
  • Proficiency in English, written and spoken.
  • Ability to travel by car and/or air as needed.
  • Ability to lift up to 45 pounds and transport educational equipment, such as a simulator.
Responsibilities
  • Build and maintain collaborative relationships with thought leaders and healthcare providers.
  • Lead peer-to-peer scientific discussions focused on the safe and appropriate use of therapies.
  • Gather and communicate field-based insights on disease state, clinical practice, and patient management.
  • Translate complex clinical and scientific data into clear, actionable insights for echocardiography and sonography professionals.
  • Serve as a trusted scientific resource within the healthcare community.
  • Align field activities with medical strategy and evolving stakeholder needs.
Desired Qualifications
  • Experience in hypertrophic cardiomyopathy.

About the company

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS raised 2026 revenue guidance to $49.0-$50.0 billion after Q2 2026 beat.
  • Q2 2026 growth portfolio revenue rose 15%, driven by Reblozyl, Camzyos, Breyanzi.
  • Houston's $2.3 billion campus and Opdivo Qvantig support manufacturing and lifecycle defense.

What critics are saying

  • Reuters reported September 15, 2026, Amgen seeks Opdivo biosimilar entry before 2028.
  • A revived $6.7 billion Celgene CVR lawsuit threatens cash, distraction, and precedent.
  • September 22, 2026 layoffs cut 265 more New Jersey jobs through May 2027.

What makes Bristol Myers Squibb unique

  • BMS combines oncology, immunology, and cardiovascular franchises with large commercial scale.
  • Its growth portfolio, led by Eliquis, Reblozyl, Camzyos, and Breyanzi, offsets legacy decline.
  • The September 9, 2026 Houston campus adds flexible U.S. manufacturing for multiple modalities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↑ 7%

1 year growth

↑ 7%

2 year growth

↑ 7%
U.S. Securities and Exchange Commission
Sep 30th, 2026
Joint Press Release

Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers

APAC News Network
Sep 28th, 2026
Shilpi Sinha appointed GCO India Head at Johnson & Johnson.

Shilpi Sinha appointed GCO India Head at Johnson & Johnson. Summarize with: New Delhi, Sep 28(APAC Media): Shilpi Sinha has joined Johnson & Johnson Innovative Medicine as Director, Country Head - GCO India. In this role, Sinha will lead the company's Global Clinical Operations (GCO) function in India, covering areas related to clinical operations and research activities. Shilpi Sinha's New Role Sinha brings more than two decades of experience in clinical research, clinical operations, project management and quality management. Her appointment adds to Johnson & Johnson's leadership team supporting clinical development activities in India. Before joining Johnson & Johnson Innovative Medicine, Sinha spent more than 14 years at Bristol Myers Squibb. She most recently served as Director, Country Head RCO India. Experience In Clinical Research Sinha has worked across several areas of clinical research and operations during her career. At Bristol Myers Squibb, she held roles involving clinical operations, project management and quality functions. Earlier, she worked at Parexel as Project Quality Lead. She began her career with Quintiles as a Clinical Team Lead. With experience across pharmaceutical and clinical research organisations, Sinha's new role will focus on the company's Global Clinical Operations activities in India. Her career spans more than 20 years across clinical trials, research operations and quality management. Summarize with:

Yahoo Finance
Sep 24th, 2026
Bristol Myers Squibb vs Pfizer: which healthcare stock is a better buy in 2026?

Bristol Myers Squibb and Pfizer, two pharmaceutical giants facing patent cliffs on blockbuster drugs, are taking divergent approaches to growth. Bristol Myers focuses on oncology and immunology whilst Pfizer leverages pandemic-era cash for acquisitions in high-growth areas like obesity treatments. Bristol Myers reported FY 2025 revenue of $48.2 billion, down 0.2% year-over-year, with net income of $7.1 billion and a 14.6% net margin. The company maintains a debt-to-equity ratio of 2.6x and generated $12.8 billion in free cash flow. Pfizer's FY 2025 revenue totalled $62.6 billion, declining 1.6%, with net income of $7.8 billion and a 12.4% net margin. Recent acquisitions include Seagen and Metsera, positioning the firm in oncology and obesity markets. Both companies partner with distributors and maintain global operations across multiple therapeutic areas.

BridgeTower Media
Sep 22nd, 2026
Bristol Myers Squibb to cut 265 more jobs in New Jersey (updated).

Bristol Myers Squibb to cut 265 more jobs in New Jersey (updated). In a notice with the New Jersey Department of Labor & Workforce Development, the pharmaceutical giant said it plans to let go 265 employees between December and May 2027. "Bristol Myers Squibb is executing its strategy to build for sustainable, long-term growth, and that work is reflected in our performance. We continue to align our resources and organizational structure to meet the demands of a rapidly evolving landscape," a company spokesperson shared with NJBIZ. "These efforts help us operate more efficiently, create flexibility to invest in growth opportunities and our differentiated pipeline, and continue delivering long-term value for patients, colleagues, and shareholders." The representative added that the latest notice applies to some New Jersey-based employees as well as some field employees who are not in New Jersey but report to sites in the state. Cutting costs. Since then, the company has issued more than 1,800 pink slips in New Jersey. As with the most recent notice, some of those employees were based at the company's headquarters as well as some in the field. The latest disclosure comes about five months after BMS said it would eliminate 206 jobs between July and December. During the company's first-quarter earnings call in April, BMS said it had achieved more than $1 billion in savings through its productivity initiative in 2025. It also said the company remains on track to deliver the remaining $1 billion in annual cost savings by the end of 2027. Company executives have said they are reinvesting a portion of those savings into innovation in areas with high unmet need, such as oncology, hematology, fibrosis and cardiovascular. The latest cost-cutting campaign came less than a year after BMS unveiled plans to save $1.5 billion via the layoff of some 2,220 employees globally. That resulted in more than 1,300 eliminated positions locally in 2024. Editor's note: This story was updated at 1:56 p.m. Sept. 22, 2026, to include a statement from a Bristol Myers Squibb spokesperson.

InnovationMap
Sep 21st, 2026
Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston.

Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston. Sep 21, 2026, 1:00 pm The site will manufacture Lilly's first synthetic oral GLP-1 medication and other advanced therapeutics. Photo via gov.texas.gov Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park. The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, as well as other advanced therapeutics. "We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas," David Ricks, Lilly chair and CEO, said in a prepared statement. "This $6.5 billion investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly's latest products from Texas to people here at home and around the world." Houston was up against more than 300 locations in the U.S. for the factory, as part of Lilly's $50 billion investment in domestic medicine production that has launched 10 manufacturing sites since 2020. Lilly first announced Houston had been selected for the site last September. Photo via gov.texas.gov As Abbott mentioned, the site is expected to create hundreds of jobs, and will hire engineers, scientists, operations personnel and lab technicians once up and running. It will create 4,000 construction jobs while being built. In an effort to support workforce development, Lilly also announced a $12.5 million commitment to Houston's San Jacinto College in addition to a $2.5 million charitable donation to the San Jacinto College Foundation. The funding will go toward hands-on training, equipment and facilities to support future technicians, operators, maintenance professionals, and other manufacturing talent, according to Lilly. The charitable donation will fund scholarships for students. "This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region," Brenda Hellyer, chancellor of San Jacinto College, said in the release. "When you invest in a place like Houston, you invest in its people first," Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home." Rendering courtesy Eli Lilly Lilly previously said it chose Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, because of factors such as financial incentives, access to utilities and transportation and the region's business-friendly environment. Generation Park is home to campuses for San Jacinto College and Lone Star College. Since Lilly first announced plans for the site, another fellow pharma giant has made plans to move into Generation Park. Bristol Myers Squibb Co. announced last month that it would build a $2.3 billion factory in the district. The site is expected to manufacture small molecule, biologic and antibody-drug conjugates and will also come online around 2030. Read more here.